Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2015 autoinjector versus pre-filled syringe bioequivalence study in healthy male volunteers
NL-OMON40923Active, not recruiting
- Sponsor
- Hexal AG
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of omalizumab biosimilar SYN008 in rheumatoid arthritis (RA), psoriasis and autoimmune disease (2 arms), sponsored by Hexal AG. Primary endpoint: Bioequivalence. Started Mar 2014; status: active, not recruiting.
02
Drugs
omalizumab biosimilar SYN008
03
Conditions
rheumatoid arthritis (RA)psoriasisautoimmune disease
Beyond the preview
Go deeper on NL-OMON40923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40923.